Metformin inhibits stromal aromatase expression and tumor progression in a rodent model of postmenopausal breast cancer
Abstract Background Obesity and type II diabetes are linked to increased breast cancer risk in postmenopausal women. Patients treated with the antidiabetic drug metformin for diabetes or metabolic syndrome have reduced breast cancer risk, a greater pathologic complete response to neoadjuvant therapy...
Main Authors: | Erin D. Giles, Sonali Jindal, Elizabeth A. Wellberg, Troy Schedin, Steven M. Anderson, Ann D. Thor, Dean P. Edwards, Paul S. MacLean, Pepper Schedin |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-06-01
|
Series: | Breast Cancer Research |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13058-018-0974-2 |
Similar Items
-
Preventing ovariectomy-induced weight gain decreases tumor burden in rodent models of obesity and postmenopausal breast cancer
by: Elizabeth A. Wellberg, et al.
Published: (2022-06-01) -
Effects of aromatase inhibitor therapy on adiposity and cardiometabolic health in postmenopausal women: a controlled cohort extension study
by: Yee-Ming M Cheung, et al.
Published: (2023-09-01) -
Metformin alleviates stress-induced cellular senescence of aging human adipose stromal cells and the ensuing adipocyte dysfunction
by: Laura Le Pelletier, et al.
Published: (2021-09-01) -
Immune Milieu Established by Postpartum Liver Involution Promotes Breast Cancer Liver Metastasis
by: Alexandra Q. Bartlett, et al.
Published: (2021-04-01) -
Metformin Increases Proliferative Activity and Viability of Multipotent Stromal Stem Cells Isolated from Adipose Tissue Derived from Horses with Equine Metabolic Syndrome
by: Agnieszka Smieszek, et al.
Published: (2019-01-01)